We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of ALXN2050 in Participants With Renal Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04623710
Recruitment Status : Completed
First Posted : November 10, 2020
Last Update Posted : October 14, 2022
Sponsor:
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with impaired renal function.

Condition or disease Intervention/treatment Phase
Renal Impairment Healthy Drug: ALXN2050 Phase 1

Detailed Description:
The study will initiate (Part 1) with participants with severe impaired renal function (Cohort 1) and their matched healthy control participants (Cohort 4). Following data review, the study may proceed (Part 2) with participants with moderate (Cohort 2) and mild (Cohort 3) impaired renal function if deemed necessary.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, Open-Label, Multiple-Dose, Parallel Study to Determine the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ALXN2050 in Adult Participants
Actual Study Start Date : July 8, 2021
Actual Primary Completion Date : February 18, 2022
Actual Study Completion Date : March 21, 2022

Arm Intervention/treatment
Experimental: Cohort 1: Severe Impaired Renal Function
Participants will receive ALXN2050.
Drug: ALXN2050
ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Other Name: ACH-0145228 (formerly)

Experimental: Cohort 2: Moderate Impaired Renal Function
Participants will receive ALXN2050.
Drug: ALXN2050
ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Other Name: ACH-0145228 (formerly)

Experimental: Cohort 3: Mild Impaired Renal Function
Participants will receive ALXN2050.
Drug: ALXN2050
ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Other Name: ACH-0145228 (formerly)

Experimental: Cohort 4: Healthy Control
Participants will receive ALXN2050.
Drug: ALXN2050
ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Other Name: ACH-0145228 (formerly)




Primary Outcome Measures :
  1. Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point (AUC0-12) Of Plasma ALXN2050 After Steady-state [ Time Frame: Up to 72 hours postdose ]
  2. Area Under The Concentration-time Curve Calculated To The Last Observable Concentration At Time t (AUCt) Of Plasma ALXN2050 After Steady-state [ Time Frame: Up to 72 hours postdose ]
  3. Maximum (Peak) Steady-state Plasma Concentration (Cmax,ss) Of Plasma ALXN2050 [ Time Frame: Up to 72 hours postdose ]
  4. Time To Reach Maximum (Peak) Plasma Concentration Following ALXN2050 Administration At Steady-state (Tmax,ss) [ Time Frame: Up to 72 hours postdose ]

Secondary Outcome Measures :
  1. Change From Baseline In Complement Factor D Concentration At 24, 48, And 72 Hours Postdose [ Time Frame: Baseline, 24, 48, and 72 hours postdose ]
  2. Change From Baseline In Plasma b Fragment Of Complement Factor B Concentration [ Time Frame: Baseline, up to 72 hours postdose ]
  3. Change From Baseline In Complement Alternative Pathway Activity [ Time Frame: Baseline, up to 72 hours postdose ]
  4. Number Of Participants Receiving ALXN2050 With Treatment-emergent Adverse Events [ Time Frame: Day 1 (postdose) through follow-up (30 [+/- 2] days after last study drug administration)] ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Body weight must be at least 50.0 kilograms (kg) and body mass index (BMI) within the range of 18.0 - 40.0 kg/meter squared (m^2) (inclusive) at the time of signing the informed consent.
  2. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  3. Must agree to receive prophylactic antibiotics to mitigate the potential risk of meningococcal infection.

    Participants with Impaired Renal Function

  4. Aside from impaired renal function, sufficiently healthy for study participation based upon medical history, physical examination, neurological examination, laboratory tests, vital signs, and electrocardiograms (ECGs).
  5. A clinical diagnosis of impaired stable renal function.
  6. No clinically significant change in renal status at least 1 month prior to first dose of study intervention and is not currently or has not previously been on hemodialysis or did not have any history of peritoneal dialysis.
  7. Stable creatinine clearance.
  8. Must be on a stable medication regimen. Concomitant medications must be approved by Alexion unless presented in the list of common concurrent medications for participants with impaired renal function.

    Matched Healthy Control Participants with Normal Renal Function

  9. Must match the sex and the race (similar ratio of white and non-white) of participants with impaired renal function, and at screening, age must be within ± 10 years and BMI must be within ± 20% of the matching participants with impaired renal function
  10. Healthy as determined by medical evaluation, including medical history, physical examination, neurological examination, laboratory tests, vital signs, and ECGs, and who possess a baseline eGFR ≥ 90 mL/min/1.73 m^2, based on MDRD equation at screening.

Exclusion Criteria:

  1. History or presence of seizures, head injury, head trauma, or any other brain disorder.
  2. History of procedures that could alter absorption or excretion of orally administered drugs.
  3. History of meningococcal infection or a first-degree relative with a history of meningococcal infection.
  4. Body temperature ≥38.0°Celcius at screening or check-in or history of febrile illness or other evidence of infection, systemic or otherwise, within 14 days prior to the first dose of study intervention.
  5. Participants with CH50 results outside the reference ranges at screening, unless approved by Alexion
  6. Significant blood loss or donation of blood within 3 months prior to the first dose of study intervention, donation of plasma within 30 days prior to the first dose of study intervention, receipt of blood products within 6 months prior to first dose of study intervention, or receipt of a vaccine within 30 days prior to the first dose of study intervention.
  7. Current enrollment or past participation within the last 30 days (or 5 half-lives, whichever is longer) prior to the first dose of study intervention in the current clinical study or any other clinical study involving an investigational study intervention or any other type of medical research.
  8. History or presence of drug or alcohol abuse within 1 year prior to the first dose of study intervention, current tobacco user, or positive results for alcohol and/or drug screen at screening or check-in.
  9. Pregnant or lactating.
  10. Does not produce sufficient urine output to permit urine sampling at screening and/or check-in or has a history of urinary incontinence prior to check-in.
  11. History of kidney transplant or actively on a transplant waiting list prior to check-in.
  12. Any acute or chronic non-renal condition prior to check-in that would limit the participant's ability to complete or participate in this clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04623710


Locations
Layout table for location information
United States, Florida
Clinical Trial Site
Hialeah, Florida, United States, 33014
Clinical Trial Site
Orlando, Florida, United States, 32809
Sponsors and Collaborators
Alexion Pharmaceuticals
Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04623710    
Other Study ID Numbers: ALXN2050-HV-108
First Posted: November 10, 2020    Key Record Dates
Last Update Posted: October 14, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alexion Pharmaceuticals:
Factor D Inhibitor
Pharmacokinetics
Pharmacodynamics
Safety
ALXN2050
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases